Cytokinetics (CYTK) Research & Development (2010 - 2026)

Cytokinetics (CYTK) has reported Research & Development for 17 consecutive years, with $95.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 2.79% year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $411.7 million (up 15.62% YoY), while the FY2025 annual figure was $416.0 million, up 22.57% from the prior year.
• Research & Development slipped to $95.5 million in Q1 2026 per CYTK's latest filing, from $104.4 million in the prior quarter.
• Across five years, Research & Development topped out at $112.6 million in Q2 2025 and bottomed at $45.9 million in Q1 2022.
• Historically, Research & Development has averaged $83.5 million across 5 years, with a median of $83.2 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development soared 72.9% — and 2024, when it decreased 4.32%.
• Cytokinetics' Research & Development stood at $75.0 million in 2022, then climbed by 13.27% to $85.0 million in 2023, then gained by 10.18% to $93.6 million in 2024, then climbed by 11.5% to $104.4 million in 2025, then fell by 8.5% to $95.5 million in 2026.
• Business Quant data shows CYTK's Research & Development at $95.5 million in Q1 2026, $104.4 million in Q4 2025, and $99.2 million in Q3 2025.